|
1
|
Roci E, Cakani B, Brace G, Bushati T,
Rroji A, Petrela M and Kaloshi G: Platinum-based chemotherapy in
recurrent high-grade glioma patients: Retrospective study. Med
Arch. 68:140–143. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Feng B, Hu P, Lu SJ, Chen JB and Ge RL:
Increased argonaute 2 expression in gliomas and its association
with tumor progression and poor prognosis. Asian Pac J Cancer Prev.
15:4079–4083. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sai K, Yang QY, Shen D and Chen ZP:
Chemotherapy for gliomas in mainland China: An overview. Oncol
Lett. 5:1448–1452. 2013.PubMed/NCBI
|
|
4
|
Watts C, Price SJ and Santarius T: Current
concepts in the surgical management of glioma patients. Clin Oncol
(R Coll Radiol). 26:385–394. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahmed R, Oborski MJ, Hwang M, Lieberman FS
and Mountz JM: Malignant gliomas: Current perspectives in
diagnosis, treatment and early response assessment using advanced
quantitative imaging methods. Cancer Manag Res. 6:149–170.
2014.PubMed/NCBI
|
|
6
|
Kleihues P, Louis DN, Scheithauer BW,
Rorke LB, Reifenberger G, Burger PC and Cavenee WK: The WHO
classification of tumors of the nervous system. J Neuropathol Exp
Neurol. 61:215–225. 2002.PubMed/NCBI
|
|
7
|
Adida C, Crotty PL, McGrath J, Berrebi D,
Diebold J and Altieri DC: Developmentally regulated expression of
the novel cancer anti-apoptosis gene survivin in human and mouse
differentiation. Am J Pathol. 152:43–49. 1998.PubMed/NCBI
|
|
8
|
Editorial Committee of Chinese Journal of
Pathology: The meeting summary of the national symposium on
immunohistochemical technique and diagnosis standard. Zhonghua Bing
Li Xue Za Zhi. 25:326–328. 1996.(In Chinese).
|
|
9
|
Shankar SL, Mani S, O'Guin KN, Kandimalla
ER, Agrawal S and Shafit-Zagardo B: Survivin inhibition induces
human neural tumor cell death through caspase-independent and
-dependent pathways. J Neurochem. 79:426–436. 2001.PubMed/NCBI
|
|
10
|
Parenti A, Leo G, Porzionato A, Zaninotto
G, Rosato A and Ninfo V: Expression of survivin, p53 and caspase 3
in Barrett's esophagus carcinogenesis. Hum Pathol. 37:16–22. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pan Y, Hu WH, Xie D, et al: Nuclear and
cytoplasmic expressions of survivin in glioma and their prognostic
value. Zhonghua Yi Xue Za Zhi. 87:325–329. 2007.(In Chinese).
PubMed/NCBI
|
|
12
|
Ene CI and Holland EC: Personalized
medicine for gliomas. Surg Neurol Int. 6(Suppl 1): S89–S95.
2015.PubMed/NCBI
|
|
13
|
Wilden JA, Voorhies J, Mosier KM, O'Neill
DP and Cohen-Gadol AA: Strategies to maximize resection of complex,
or high surgical risk, low-grade gliomas. Neurosurg Focus.
34:E52013. View Article : Google Scholar
|
|
14
|
Honda R, Körner R and Nigg EA: Exploring
the functional interactions between Aurora B, INCENP and survivin
in mitosis. Mol Biol Cell. 14:3325–3341. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Al-Khalaf HH, Lach B, Allam A, et al:
Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and
induction of apoptosis in response to radiation and cisplatin in
meningioma cells. Brain Res. 1188:25–34. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chung CH, Zhang Q, Kong CS, et al: p16
protein expression and human papillomavirus status as prognostic
biomarkers of nonoropharyngeal head and neck squamous cell
carcinoma. J Clin Oncol. 32:3930–3938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kamb A: Role of a cell cycle regulator in
hereditary and sporadic cancer. Cold Spring Harb Symp Quant Biol.
59:39–47. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Söling A, Plugge EM, Schmitz M, et al:
Autoantibodies to the inhibitor of apoptosis protein survivin in
patients with brain tumors. Int J Oncol. 30:123–128.
2007.PubMed/NCBI
|
|
19
|
Hassounah M, Lach B, Allam A, et al:
Benign tumors from the human nervous system express high levels of
survivin and are resistant to spontaneous and radiation-induced
apoptosis. J Neurooncol. 72:203–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bongiovanni L, Di Diodoro F, Della Salda L
and Brachelente C: On the role of survivin as a stem cell biomarker
of canine hair follicle and related tumours. Vet Dermatol.
25:138–141. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khan S, Bennit HF, Turay D, Perez M,
Mirshahidi S, Yuan Y and Wall NR: Early diagnostic value of
survivin and its alternative splice variants in breast cancer. BMC
Cancer. 14:1762014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kogiku M, Ohsawa I, Matsumoto K, Sugisaki
Y, Takahashi H, Teramoto A and Ohta S: Prognosis of glioma patients
by combined immunostaining for survivin, Ki-67 and epidermal growth
factor receptor. J Clin Neurosci. 15:1198–1203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saito T, Arifin MT, Hama S, et al:
Survivin subcellular localization in high-grade astrocytomas:
Simultaneous expression in both nucleus and cytoplasm is negative
prognostic marker. J Neurooncol. 82:193–198. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nandi S, Ulasov IV, Tyler MA, et al:
Low-dose radiation enhances survivin-mediated virotherapy against
malignant glioma stem cells. Cancer Res. 68:5778–5784. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy. Expert Opin Ther Targets.
12:463–476. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen LH, Li YW, Gao LY and Liu JF: An
evaluation for the function and significance concerned to
alternations of p16 3D structure with gene mutation in esophageal
squamous cell carcinoma. Chin J Med Genet. 23:208–212. 2006.
|
|
27
|
Selemetjev S, Dencic TI, Marecko I,
Jankovic J, Paunovic I, Savin S and Cvejic D: Evaluation of
survivin expression and its prognostic value in papillary thyroid
carcinoma. Pathol Res Pract. 210:30–34. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Piaton E, Carré C, Advenier AS, et al: p16
INK4a overexpression and p16/Ki-67 dual labeling versus
conventional urinary cytology in the evaluation of urothelial
carcinoma. Cancer Cytopathol. 122:211–220. 2014. View Article : Google Scholar : PubMed/NCBI
|
